XBiotech
XBIT
64 hedge funds and large institutions have $34.9M invested in XBiotech in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more funds holding
Funds holding: 61 → 64 (+3)
0.59% less ownership
Funds ownership: 13.84% → 13.25% (-0.59%)
26% less capital invested
Capital invested by funds: $46.8M → $34.9M (-$12M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$520K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$414K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$293K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$269K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$1.15M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$580K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$394K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$392K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$341K |
XBIT Hedge Fund Activity: Q1 2022 in Review
64 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2022, worth a combined $34.9M — down 26% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XBIT positions and 7 closed out — a net gain of 3 holders — while 13 added to existing stakes and 23 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $520K. The largest seller was State Street, cutting an estimated $1.15M.
- 64 institutional investors held XBiotech (XBIT) as of Q1 2022, up from 61 in Q4 2021.
- Funds reported $34.9M of XBiotech stock for Q1 2022, down 26% quarter-over-quarter.
- 10 funds opened new XBiotech positions in Q1 2022 and 7 closed out, a net change of +3 holders.
- The largest XBiotech buyer in Q1 2022 was Dimensional Fund Advisors, an estimated $520K added.
- The largest XBiotech seller in Q1 2022 was State Street, an estimated $1.15M sold.
Based on aggregated 13F filings for Q1 2022.